They analyzed immunohistochemistry and digital pathology tumor specimens derived from relapsed glioblastoma, either regorafenib treated or not, and hypothesized that regorafenib treatment induced AMPK activation with metabolic reprogramming, eventually leading to an impairment of cell proliferation. The gene discussed is PRKAA2; the disease is glioblastoma.